Barclays lowered the firm’s price target on Bruker (BRKR) to $40 from $43 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives
- Bruker Raises $669.5 Million Through Underwriting Agreement
- Bruker Positioned for Growth with Strategic Financial Moves and Cost Savings Initiatives
- Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
- Bruker falls -11.3%